Recent research have centered on the convergence of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GCGR stimulators are commonly employed for managing type 2 T2DM, their emerging effects on reinforcement circuits, specifically mediated by DA systems, are